CareDx (STU:1K9) Cyclically Adjusted Revenue per Share: €4.73 (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

STU:1K9 CareDx Inc STU:1K9
70 GF Score
Price €41.20
GF Value €21.91
Valuation Significantly Overvalued
! 7 Warning Signs
View Full Analysis

What is CareDx Cyclically Adjusted Revenue per Share?

CareDx STU:1K9 70 Cyclically Adjusted Revenue per Share is €4.73 as of Jun. 2026. GuruFocus rates STU:1K9 with a GF Score™ of 70/100 and a GF Value™ of €21.91 (Significantly Overvalued). The stock has 7 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

CareDx's adjusted revenue per share for the three months ended in Jun. 2026 was €2.144. Add all the adjusted revenue per share for the past 10 years together and divide the count will get our Cyclically Adjusted Revenue per Share, which is €4.73 for the trailing ten years ended in Jun. 2026.

During the past 12 months, CareDx's average Cyclically Adjusted Revenue Growth Rate was 14.80% per year. During the past 3 years, the average Cyclically Adjusted Revenue Growth Rate was 9.20% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Revenue Growth Rate using Cyclically Adjusted Revenue per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted Revenue Growth Rate of CareDx was 9.20% per year. The lowest was 9.20% per year. And the median was 9.20% per year.

As of today (2026-08-13), CareDx's current stock price is €41.20. CareDx's Cyclically Adjusted Revenue per Share for the quarter that ended in Jun. 2026 was €4.73. CareDx's Cyclically Adjusted PS Ratio of today is 8.71.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of CareDx was 8.70. The lowest was 1.22. And the median was 3.56.


CareDx  (STU:1K9) Cyclically Adjusted Revenue per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Revenue per Share may underestimate the company's revenue. Cyclically Adjusted PS Ratio can seem to be too high even the actual PS Ratio is low.

For the Cyclically Adjusted PS Ratio, the revenue per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/S calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PS Ratio is also called CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

CareDx's Cyclically Adjusted PS Ratio of today is calculated as

Cyclically Adjusted PS Ratio=Share Price/Cyclically Adjusted Revenue per Share
=41.20/4.73
=8.71

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of CareDx was 8.70. The lowest was 1.22. And the median was 3.56.


Be Aware

Cyclically Adjusted PS Ratio works better for cyclical companies. It gives you a better idea on the company's real revenue value.


CareDx Cyclically Adjusted Revenue per Share Related Terms


CareDx Cyclically Adjusted Revenue per Share Historical Data

* Premium members only.

The historical data trend for CareDx's Cyclically Adjusted Revenue per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

CareDx Cyclically Adjusted Revenue per Share Chart

CareDx Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted Revenue per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 3.55 3.93 4.17 4.28

CareDx Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Cyclically Adjusted Revenue per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 4.00 4.20 4.28 4.49 4.73

STU:1K9 vs NEO, WGS, PSNL: Cyclically Adjusted Revenue per Share Comparison

For the Diagnostics & Research subindustry, CareDx's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


CareDx Cyclically Adjusted PS Ratio vs Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, CareDx's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where CareDx's Cyclically Adjusted PS Ratio falls into.


STU:1K9
70GF Score
CareDx Inc STU:1K9
Cyclically Adjusted Revenue per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

CareDx Cyclically Adjusted Revenue per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

What is Cyclically Adjusted Revenue per Share? How do we calculate Cyclically Adjusted Revenue per Share?

Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Revenue per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the revenue per share from 2001 through 2010.

We adjusted the 2001 revenue per share data with the total inflation from 2001 through 2010 to the equivalent revenue in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's revenue is $1 a share in 2001, then the 2001's equivalent revenue in 2010 is $1.4 a share. If Wal-Mart's revenue is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 revenue in 2010 is $1.35. So on and so forth, you get the equivalent revenue per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, CareDx's adjusted Revenue per Share data for the three months ended in Jun. 2026 was:

Adj_RevenuePerShare= Revenue per Share /CPI of Jun. 2026 (Change)*Current CPI (Jun. 2026)
=2.144/333.9520*333.9520
=2.144

Current CPI (Jun. 2026) = 333.9520.

CareDx Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201609 0.571 241.428 0.790
201612 0.483 241.432 0.668
201703 0.507 243.801 0.694
201706 0.501 244.955 0.683
201709 0.454 246.819 0.614
201712 0.377 246.524 0.511
201803 0.385 249.554 0.515
201806 0.429 251.989 0.569
201809 0.489 252.439 0.647
201812 0.515 251.233 0.685
201903 0.553 254.202 0.726
201906 0.661 256.143 0.862
201909 0.724 256.759 0.942
201912 0.759 256.974 0.986
202003 0.811 258.115 1.049
202006 0.830 257.797 1.075
202009 0.924 260.280 1.186
202012 0.977 260.474 1.253
202103 1.106 264.877 1.394
202106 1.179 271.696 1.449
202109 1.220 274.310 1.485
202112 1.326 278.802 1.588
202203 1.360 287.504 1.580
202206 1.432 296.311 1.614
202209 1.498 296.808 1.685
202212 1.453 296.797 1.635
202303 1.345 301.836 1.488
202306 1.205 305.109 1.319
202309 1.162 307.789 1.261
202312 1.126 306.746 1.226
202403 1.282 312.332 1.371
202406 1.642 314.175 1.745
202409 1.412 315.301 1.496
202412 1.187 315.605 1.256
202503 1.418 319.799 1.481
202506 1.384 322.561 1.433
202509 1.586 324.800 1.631
202512 1.811 324.054 1.866
202603 1.916 330.213 1.938
202606 2.144 333.952 2.144

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

What does a Cyclically Adjusted Revenue per Share of €4.73 mean?
CareDx (STU:1K9) has a Cyclically Adjusted Revenue per Share of €4.73 as of Jun. 2026. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on CareDx and its competitors.
Is CareDx's Cyclically Adjusted Revenue per Share too high?
CareDx's current Cyclically Adjusted Revenue per Share is €4.73. Overall, CareDx has a GF Score™ of 70/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does CareDx's Cyclically Adjusted Revenue per Share compare to NEO and WGS?
CareDx's Cyclically Adjusted Revenue per Share of €4.73 can be compared against companies in the Medical Diagnostics & Research industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted Revenue per Share for a Medical Diagnostics & Research company?
A good Cyclically Adjusted Revenue per Share depends on the Medical Diagnostics & Research industry context. However, Cyclically Adjusted Revenue per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted Revenue per Share mean?
A high Cyclically Adjusted Revenue per Share can signal that a stock is expensive relative to its fundamentals. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on CareDx and its competitors. CareDx's current Cyclically Adjusted Revenue per Share is €4.73. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is CareDx stock overvalued right now?
Based on GuruFocus' analysis, CareDx (STU:1K9) is currently considered Significantly Overvalued. The stock's GF Value™ is €21.91, compared to a current price of €41.20 — trading 88% above its estimated fair value. The current Cyclically Adjusted Revenue per Share is €4.73. CareDx's overall GF Score™ is 70/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted Revenue per Share calculated?
Cyclically Adjusted Revenue per Share is calculated from a company's financial statements. For CareDx (STU:1K9), the current Cyclically Adjusted Revenue per Share is €4.73 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is CareDx (STU:1K9) Overvalued in 2026?

Based on GuruFocus' analysis, CareDx stock appears to be overvalued. The current stock price of €41.20 is trading 88% above its estimated GF Value™ of €21.91. GuruFocus considers CareDx to be Significantly Overvalued.

Key valuation signals for STU:1K9:

  • Cyclically Adjusted Revenue per Share: €4.73
  • GF Value™: €21.91 vs. price of €41.20 (88% above fair value)
  • GF Score™: 70/100 with 7 warning signs

No single metric tells the full story. See the STU:1K9 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


CareDx Business Description

Other Exchanges CDNA:USA
Address 8000 Marina Boulevard, Brisbane, CA, USA, 94005
CareDx Inc operates as a precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers. It offers testing services, products, and digital solutions along with the pre- and post-transplant patient journey and is a provider of genomics-based information for transplant patients. The Company's commercially available testing services consist of AlloSure Kidney, AlloMap Heart, AlloSure Heart, a dd-cfDNA solution for heart transplant patients, and AlloSure Lung, a dd-cfDNA solution for lung transplant patients. Geographically it generates the majority of its revenue from the United States. The company generates the majority of revenue from the Testing services.
70GF Score

Get the complete analysis for STU:1K9

Cyclically Adjusted Revenue per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€41.20
Price
€21.91
GF Value